NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
Open Access
- 5 June 2007
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 97 (1) , 105-111
Abstract
Breast cancer is globally the most common malignancy in women. Her2-targeted monoclonal antibodies are established treatment modalities, and vaccines are in late-stage clinical testing in patients with breast cancer and known to promote tumour-killing through mechanisms like antibody-dependent cellular cytotoxicity. It is therefore increasingly important to study immunological consequences of conventional treatment strategies. In this study, functional tests and four-colour flow cytometry were used to detect natural killer (NK)-cell functions and receptors as well as T-cell signal transduction molecules and intracellular cytokines in preoperative breast cancer patients, and patients who had received adjuvant radiotherapy or adjuvant combined chemo-radiotherapy as well as in age-matched healthy controls. The absolute number of NK cells, the density of NK receptors as well as in vitro quantitation of functional NK cytotoxicity were significantly higher in preoperative patients than the post-treatments group and controls. A similar pattern was seen with regard to T-cell signalling molecules, and preoperative patients produced significantly higher amounts of cytokines in NK and T cells compared to other groups. The results indicate that functions of NK and T cells are well preserved before surgery but decrease following adjuvant therapy, which may speak in favour of early rather than late use of immunotherapeutic agents such as trastuzumab that may depend on intact immune effector functions.Keywords
This publication has 27 references indexed in Scilit:
- Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trialBritish Journal of Cancer, 2006
- Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65Vaccine, 2006
- Thymic regulatory T cellsAutoimmunity Reviews, 2005
- Cytotoxic T Lymphocyte Count and Survival Time in Women with Metastatic Breast CancerThe Breast Journal, 2004
- Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1AInternational Journal of Cancer, 2003
- Preferential apoptosis of CD56dim natural killer cell subset in patients with cancerEuropean Journal of Immunology, 2002
- Defective expression and function of natural killer cell–triggering receptors in patients with acute myeloid leukemiaBlood, 2002
- Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma modelCancer Immunology, Immunotherapy, 2002
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Interleukin-2 augments natural killer cell activityNature, 1981